Table 4.
Univariate analysis for the patients with or without upgraded tumors
| Upgraded n (%) | Not upgraded n (%) | p | |
|---|---|---|---|
| Age (years) | |||
| <70 | 72 (96.0) | 200 (93.0) | 0.35 |
| ≥70 | 3 (4.0) | 15 (7.0) | |
| Menopause status | 0.88 | ||
| Premenopausal | 22 (29.3) | 65 (30.2) | |
| Postmenopausal | 53 (70.7) | 150 (69.8) | |
| BMI | 0.19 | ||
| <30 | 39 (52.0) | 93 (43.3) | |
| ≥30 | 36 (48.0) | 122 (56.7) | |
| DM | 15 (20.0) | 58 (27.0) | 0.23 |
| HT | 36 (48.0) | 86 (40.0) | 0.22 |
| Final FIGO stage | 0.003* | ||
| I | 46 (61.3) | 204 (78.4) | |
| II | 9 (12.0) | 16 (6.2) | |
| III | 10 (13.3) | 26 (10.0) | |
| IV | 10 (12.3) | 14 (5.4) | |
| LNI | 59 (78.7) | 226 (86.9) | 0.07 |
| Positive Cytology | 14 (18.7) | 26 (10.0) | 0.04 |
| LVSI | 23 (30.7) | 65 (27.0) | 0.32 |
| Depth of MI | 0.59 | ||
| <1/2 | 48 (64.0) | 175 (67.3) | |
| >1/2 | 27 (36.0) | 85 (32.7) | |
BMI: body mass index, DM: diabetes mellitus, HT: hypertension, LNI: lymph node invasion, LVSI: lymphovascular space invasion, MI: myometrial invasion
*
X2 test for trend